Health/Medical: Anadis' cancer related Mucositis Project awarded with VISTECH grant

Melbourne, Australia - Anadis Ltd. (ASX:ANX; OTC:ANDIY) an Australian biopharmaceutical company has been awarded a product development grant for its Cancer-related Alimentary Mucositis project.

The award was one of only three made by the VISTECH bi-national fund, following a competitive process, which included a thorough scientific assessment.

The fund was established by the Government of Victoria (Australia) and the Government of Israel through the Office of the Chief Scientist in its Ministry of Industry Trade and Labor.

The intended product for the oncology market will leverage a special formulation of Anadis' immune milk-derived anti LPS antibodies, growth factors and other bioactives delivered using Anadis' oral delivery technology.

Mr Gavin Jennings, Victorian Minister for Innovation stated: "(The) projects will lead to new health and sustainability-related products that will improve Victoria's quality of life and create more skilled jobs. VISTECH demonstrates the value of international partnerships in commercialising our research and highlights what Victoria can offer such partnerships on the world stage."

The first installment of the grant (overall grant is $500,000 over 18 months), was awarded to Anadis and its Israeli
collaborator, Maya BioTech, with whom Anadis will explore an innovative delivery device.

Anadis anticipates that a commercial product to broadly address Alimentary (GI and Oral) Mucositis using its milk derived antibodies and other proteins would reach the market in 2-3 years given the product's excellent safety profile.

Mucositis is a significant side effect in cancer therapy (between 20% and 100% of patients, depending on the type of cancer and treatment).

It is characterized by intestinal tissue destruction throughout the GI tract, including painful mouth ulcerations.

In the U.S. alone there are more than 10 million patients undergoing cancer treatments and 1.5 million new cancer cases per year.

There are currently no effective treatments for GI Mucositis available in the marketplace and treatment for Oral Mucositis is very expensive and limited to a narrow group of eligible patients.

Anadis' clinical studies will be initially conducted at Tel Aviv Sourasky Medical Center.

It is one of the largest hospitals in Israel with teaching and research centers affiliated with the Sackler School of Medicine, Tel Aviv University.

The study at Tel Aviv Medical Center is led by Professor Nachum Vaisman, the head of Clinical Nutrition and by Professor Zamir Halpern, the head of the Gastrointestinal Institute.

Dr. Zeil Rosenberg, CEO of Anadis said: "Oral and GI tract mucositis are health issues that affect a significant portion of the patient population. The pain and discomfort of Mucositis is among the top reasons for people to stop their cancer therapy and is also correlated with poor disease outcome.

"We hope that our product will become a new Gold Standard in cancer treatment, addressing the needs of millions of cancer patients."

Dr. Oren Fuerst, VP Business Development at Anadis said: "We continue to receive recognition to the value of our immune milk-derived platform.

"In this case, the product will have a significant impact on the cancer treatment world, enabling longer and more effective treatment to millions of patients. We also believe our product will positively impact the oncology drug and biotherapuetics industry, improving their safety profile and thereby allowing more sustained use of new products.

"We intend to partner with these companies for the benefit of cancer patients."

Keyword Tags: antibodies, cancer, milk, mucositis, oncology, polyclonal antibody ABN03530185 Anadis Dr. Oren Fuerst, +1 1 646-259-3321 VP, Business Developmentoren@anadis.com or Gran Rawlin, +61 3 9358 6388 VP, Research and Developmentgrant@anadis.com or Arie Nudel, +61 3 9358 6388 Investor Relationsarie.n@anadis.com.au

Anadis Partners with Garden State Nutritionals (GSN) for US market

Anadis Partners with Garden State Nutritionals (GSN) for US market entry of its milk-derived (colostrum) bioactive products

Melbourne, Australia (BUSINESS WIRE) - Anadis (ASX:ANX) (OTC:ANDIY), an Australian Biopharmaceutical company announced today its collaboration with Garden State Nutritionals, a New Jersey based division (GSN) of VitaQuest International in the field of dietary supplements. Anadis and GSN plans to introduce in the coming months and years a range of products, all based on Anadis' proprietary and all-natural milk-derived (colostrum) bioactives and immunoglobulins. The collaboration will allow Anadis to further expedite its penetration into the U.S. Vitamins and dietary supplements, a market which exceeds $15Bn in size, and which experiences growth rate in excess of 5% (Market research/Euro Monitor, 2007).

GSN is one of the largest custom contract manufacturers of nutritional supplements in the United States, and is a leading producer of more than $1 billion in finished retail products per year. With advanced 250,000 sq. ft. manufacturing and packaging facility they produce more than 500 million doses per month and reach all geographical areas of the United States as well as supply to all major regional and national nutritional commercial channels.

"Our expert and dedicated management team has an impressive average of more than 25 years of broad industry experience. We are thrilled to have Anadis with its proprietary Colostrum derived bioactives working with us. We see great potential in introducing Anadis to our more than 300 clients," said Jon Weisgal, VP of Marketing, VitaQuest.

Dr. Zeil Rosenberg, Anadis' New York City-based CEO, said: "GSN develops and manufacture cost-effective, market-leading dietary supplements products in every distribution channel, including health and natural food stores, mass merchandisers, network marketing and direct selling, television shopping, drug chain and direct response TV and radio."

Dr. Oren Fuerst, Anadis' New York City-based VP Business Development said: "Collaboration with GSN allows Anadis to offer our marketing partners complete turnkey solutions, including product concepts, formulations, laboratory services, package and label design, regulatory compliance and assistance in marketing and merchandising. The combination of GSN's skills with our decade of R&D in the field of dairy-derived colostrum bioactives will now allow Anadis to rapidly penetrate the U.S. vitamins and dietary supplements market. This is a four way win combination to Anadis, GSN, the dietary supplements brands under which these products will be marketed, and above all consumers, who will be offered a broad range of new products based on our proprietary, all-natural colostrum platform."

About GSN: GSN is one of the largest custom contract manufacturers of nutritional supplements in the United States. GSN has a highly skilled Product Development group, as well as a Scientific Advisory Board to help avail clients of the latest developments and technical innovations. This multidisciplinary team includes leading research scientists, molecular biologists, physicians, pharmacists, clinical nutritionists, herbalists, food technologists, and sports physiologists.

GSN's facilities are FDA-inspected and operate under strict Good Manufacturing Practices (GMP), and have earned the coveted NNFA GMP "A" Rating. GSN's kosher-approved facilities have been audited and approved by leading independent bodies.

GSN supplies dietary supplements to more than 35 countries around the world. Its Regulatory Affairs group works with customers and regional health authorities to ensure compliance in documentation requirements for each country.

About Anadis (www.anadis.com): Anadis Limited (ASX:ANX) (OTC:ANDIY) is a biopharmaceutical company producing antibodies and other bioactive proteins as health products.

Its all-natural, orally administered and colostrum-derived platform is proven safe and effective, with regulatory classification as GRAS (Generally Regarded as Safe) and BSE-free certification, allowing for rapid progression from concept to market. The company's core technology relies on advanced dairy industry processing methods including immunization of pregnant cows with proprietary antigen specific vaccines, which in turn elicit an immune response by the cow.

First-milking colostrum contains more than 35% immunoglobulin and this targeted antibody, along with other immune system bioactive nutrients, is subsequently harvested, fractionated and freeze dried under the highest dairy industry standards. The company is addressing a variety of unmet human health needs with broad market demand, including: Oral and GI Mucositis; Inflammatory Bowel Disease (IBD); Irritable Bowel Syndrome (IBS); Travellers' Diarrhea; Influenza, Clostridium Difficile and Rotavirus. The company operates from Melbourne, Australia and New York City.

Anadis Limited VP Business DevelopmentDr. Oren Fuerst, +1-646-259-3321 or en@anadis.com or Investor RelationsArie Nudel, +61 3 9358 6388 arie@anadis.com

Anadis licenses antibody technologies from ImmuCell

Melbourne, Australia - (BUSINESS WIRE) - Anadis Limited (ASX: ANX), an Australian-based biotechnology company focused on milk derived polyclonal antibodies and other milk-derived bioactives, announced today that it had signed a final agreement with ImmuCell Corporation (NASDAQ Capital Market: ICCC), a biotechnology company headquartered in Portland, Maine, USA.

Under the agreement, Anadis has licensed from ImmuCell a portfolio of issued patents, IND filings, clinical data, manufacturing plans and know-how related to several human heath product lines. In particular the deal will directly enhance product development work for Clostridium difficile, E.coli and immune deficiency related opportunistic infections. The licensed technologies are all related to the usage of hyperimmune bovine colostrum to provide immediate-acting passive immunity against infectious diseases. The royalty-based deal requires no upfront or milestone payments.

The intellectual property Anadis obtains under this agreement includes two issued U.S. patents, US Pat. No. 5,773,000 (Therapeutic treatment of Clostridium difficile-associated diseases) and US Pat.

No. 6,074,689 (Colonic delivery of protein or peptide compositions) which is applicable to a broad range of indications Anadis is pursuing using its bovine colostrum antibodies and bioactives.

Dr. Zeil Rosenberg, Anadis' CEO stated, "Beyond the issued patents, the clinical work that ImmuCell has successfully completed over many years with the U.S. Navy and Johns Hopkins University and others will expedite Anadis commercial product development to address large unmet human health needs in the US and worldwide. Having better clinical data strengthens our
ability to collaborate with pharmaceutical companies as we begin entering the US market with our product portfolio.
"Clostridium difficile or "C.diff" infection is a serious gastrointestinal bacterial and nosocomial (hospital acquired) disease among hospitalized patients worldwide. The licensed technology includes successful results from a U.S. phase II clinical study conducted by ImmuCell. C. difficile bacteria infection accounts for considerable increases in the length of hospital stays and more than $1.1 billion in health care costs each year in the United States. The bacteria infection is a common cause of significant morbidity and even death in elderly or debilitated patients (American Family Physician, 2005).The licensing arrangement will expedite Anadis' clinical trials under its Immuron joint venture with Hadassah Medical Center, Israel.

Diarrhea-related illnesses represent an important clinical target for both the military and for public health. Leveraging significant and positive clinical trial data under this agreement, Anadis intends to maintain close collaboration with the US Department of Defense and other research institutions in its efforts to develop an acceptable immediate-acting product to reduce risk from infectious diarrhea-related diseases. Such products would have a large and worldwide market.

Anadis will provide ImmuCell with access to manufacturing infrastructure and know-how for their veterinary applications, enhancing ImmuCell's ability to introduce its own veterinary products into Australia and New Zealand. Anadis shall receive a royalty on sales that are marketed under ImmuCell's own name that are produced under this collaboration in Australia. Such marketable products for the veterinary market are expected to be launched within two years.

About Anadis (www.anadis.com): Anadis Limited (ASX: ANX, OTC:ANDIY) is a biopharmaceutical company producing antibodies and other bioactive proteins as health products.

Its all-natural, orally administered and colostrum-derived platform is proven safe and effective, with regulatory classification as GRAS (Generally Regarded as Safe) and BSE-free certification, allowing for rapid progression from concept to market. The company's core technology relies on advanced dairy industry processing methods including immunization of pregnant cows with proprietary antigen specific vaccines, which in turn elicit an immune response by the cow.

First-milking colostrum contains more than 35% immunoglobulin and this targeted antibody, along with other immune system bioactive nutrients, is subsequently harvested, fractionated and freeze dried under the highest dairy industry standards. The company is addressing a variety of unmet human health needs with broad market demand, including: Oral and GI Mucositis; Inflammatory Bowel Disease (IBD); Irritable Bowel Syndrome (IBS); Travellers' Diarrhea; Influenza and Rotavirus.
The company operates from Melbourne, Australia and New York City.

Anadis LimitedCEODr. Zeil Rosenberg, +1 646-402-5289
zeil@anadis.com or VP of Business DevelopmentDr. Oren Fuerst,
+1?646-259-3321 or en@anadis.com or Investor RelationsArie
Nudel, +61 3 9358 6388 arie.n@anadis.com.au

Anadis licenses antibody technologies from ImmuCell

Melbourne, Australia - (BUSINESS WIRE) - Anadis Limited (ASX: ANX), an Australian-based biotechnology company focused on milk derived polyclonal antibodies and other milk-derived bioactives, announced today that it had signed a final agreement with ImmuCell Corporation (NASDAQ Capital Market: ICCC), a biotechnology company headquartered in Portland, Maine, USA.

Under the agreement, Anadis has licensed from ImmuCell a portfolio of issued patents, IND filings, clinical data, manufacturing plans and know-how related to several human heath product lines. In particular the deal will directly enhance product development work for Clostridium difficile, E.coli and immune deficiency related opportunistic infections. The licensed technologies are all related to the usage of hyperimmune bovine colostrum to provide immediate-acting passive immunity against infectious diseases. The royalty-based deal requires no upfront or milestone payments.

The intellectual property Anadis obtains under this agreement includes two issued U.S. patents, US Pat. No. 5,773,000 (Therapeutic treatment of Clostridium difficile-associated diseases) and US Pat.

No. 6,074,689 (Colonic delivery of protein or peptide compositions) which is applicable to a broad range of indications Anadis is pursuing using its bovine colostrum antibodies and bioactives.

Dr. Zeil Rosenberg, Anadis' CEO stated, "Beyond the issued patents, the clinical work that ImmuCell has successfully completed over many years with the U.S. Navy and Johns Hopkins University and others will expedite Anadis commercial product development to address large unmet human health needs in the US and worldwide. Having better clinical data strengthens our
ability to collaborate with pharmaceutical companies as we begin entering the US market with our product portfolio.

"Clostridium difficile or "C.diff" infection is a serious gastrointestinal bacterial and nosocomial (hospital acquired) disease among hospitalized patients worldwide. The licensed technology includes successful results from a U.S. phase II clinical study conducted by ImmuCell. C. difficile bacteria infection accounts for considerable increases in the length of hospital stays and more than $1.1 billion in health care costs each year in the United States. The bacteria infection is a common cause of significant morbidity and even death in elderly or debilitated patients (American Family Physician, 2005).The licensing arrangement will expedite Anadis' clinical trials under its Immuron joint venture with Hadassah Medical Center, Israel.

Diarrhea-related illnesses represent an important clinical target for both the military and for public health. Leveraging significant and positive clinical trial data under this agreement, Anadis intends to maintain close collaboration with the US Department of Defense and other research institutions in its efforts to develop an acceptable immediate-acting product to reduce risk from infectious diarrhea-related diseases. Such products would have a large and worldwide market.

Anadis will provide ImmuCell with access to manufacturing infrastructure and know-how for their veterinary applications, enhancing ImmuCell's ability to introduce its own veterinary products into Australia and New Zealand. Anadis shall receive a royalty on sales that are marketed under ImmuCell's own name that are produced under this collaboration in Australia. Such marketable products for the veterinary market are expected to be launched within two years.

About Anadis (www.anadis.com): Anadis Limited (ASX: ANX, OTC:ANDIY) is a biopharmaceutical company producing antibodies and other bioactive proteins as health products.

Its all-natural, orally administered and colostrum-derived platform is proven safe and effective, with regulatory classification as GRAS (Generally Regarded as Safe) and BSE-free certification, allowing for rapid progression from concept to market. The company's core technology relies on advanced dairy industry processing methods including immunization of pregnant cows with proprietary antigen specific vaccines, which in turn elicit an immune response by the cow.

First-milking colostrum contains more than 35% immunoglobulin and this targeted antibody, along with other immune system bioactive nutrients, is subsequently harvested, fractionated and freeze dried under the highest dairy industry standards. The company is addressing a variety of unmet human health needs with broad market demand, including: Oral and GI Mucositis; Inflammatory Bowel Disease (IBD); Irritable Bowel Syndrome (IBS); Travellers' Diarrhea; Influenza and Rotavirus.
The company operates from Melbourne, Australia and New York City.

Anadis LimitedCEODr. Zeil Rosenberg, +1 646-402-5289
zeil@anadis.com or VP of Business DevelopmentDr. Oren Fuerst,
+1?646-259-3321 or en@anadis.com or Investor RelationsArie
Nudel, +61 3 9358 6388 arie.n@anadis.com.au